HOME >> MEDICINE >> NEWS
Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer

Houston May 08, 2007 -- A combination of molecular-targeted therapy and hormonal therapy may be the most promising area of research for those seeking an effective treatment for ovarian cancer, according to a new review in the International Journal of Gynecological Cancer.

"Several clinical trials have confirmed the role of hormone therapy in recurrent ovarian cancer treatment, especially in patients with low-grade tumors," says review author Dr. Siqing Fu, an assistant professor of oncology at the University of Texas at Houston. "However, more research is needed to determine whether combining molecular-targeted therapy with hormonal therapy would be a more effective option."

Ovarian cancer is the deadliest of gynecological cancers; approximately 70 percent of patients are diagnosed in the later stages, when the 5-year survival rate drops below 25 percent. Traditional chemotherapy has proven to be generally ineffective against recurrent ovarian cancer, which has led researchers to investigate novel treatments.

"While a cure is unlikely, the goals of treatment are to control tumor-related symptoms and to improve or maintain quality of life," says Dr. Fu. "After surveying the latest research, combined molecular-targeted and hormonal therapy offers the greatest promise in achieving these goals and therefore deserves further investigation."


'"/>

Contact: Sean Wagner
swagner@bos.blackwellpublishing.com
781-388-8550
Blackwell Publishing Ltd.
8-May-2007


Page: 1

Related medicine news :

1. Combined imaging approach may provide better identification of difficult-to-diagnose brain clots
2. Combined therapies may boost immune response and long-term protection against brain tumors
3. Combined liver-kidney transplant beneficial for patients with dual organ disease
4. Combined contrast enhanced MRI shows promise
5. Combined treatment cuts inflammatory cells in chronic obstructive pulmonary disease
6. Combined MRI and mammography more effective at detecting breast cancer in high-risk women
7. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
8. Bulimia may result from hormonal imbalance
9. 1 in 5 early-stage breast cancer patients may not follow hormonal therapy plan
10. Genomic tests improve prediction of breast cancer response to chemotherapy, hormonal therapy
11. Some nonhormonal therapies may offer relief from hot flashes, but with possible adverse effects

Post Your Comments:
(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... readers on the “beauty of protection”. Skin Health ... through USA Today within the markets of New York, ... reach an estimated 750,000 readers. Its digital counterpart will ... online content hubs. To read more the Skin Health ...
(Date:5/29/2015)... Shaila Jiwa, a physiotherapist from Burnaby ... stated in a new announcement that patients of urinary ... commonly seen as a tabooed topic to talk about ... like Shaila Jiwa try to encourage people to come ... is a condition that can be classified under two ...
(Date:5/29/2015)... University, the first cannabis college in America, will return to Las ... demanded Basic and Advanced Classic Seminars on June ... each day. Certification is available upon completion of the seminars and ... 14 from 12:00 pm to 6:00 pm. Both the seminars and ... Casino in downtown Las Vegas. , Seminar topics covered ...
(Date:5/29/2015)... 29, 2015 The Croatia Cosmetic ... a long-lasting impression on what modern dentistry options are ... on a mission to revolutionize the perception of a ... high-class Wellness & Spa. , The top dental ... successful medical tourism agencies and led by ...
(Date:5/29/2015)... 2015 Healthpointe’s electromyography and nerve ... Los Angeles County clinics including its newest clinic ... being offered at all Healthpointe locations throughout Southern ... Bernardino County. , As the muscles contract, ... electrical impulses throughout the body and dictate whether ...
Breaking Medicine News(10 mins):Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:Patients of Urinary Incontinence Should Not "Hide And Suffer," States Physiotherapist from Burnaby Physiotherapy Clinic 2Health News:Oaksterdam University to Host Educational Cannabis Seminars and Job Fair in Las Vegas June 12 to 15; Training For Those Wanting To Work in Legal Cannabis Industry 2Health News:Oaksterdam University to Host Educational Cannabis Seminars and Job Fair in Las Vegas June 12 to 15; Training For Those Wanting To Work in Legal Cannabis Industry 3Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 2Health News:Croatian Cosmetic Dentistry Providers New Approach to Revolutionize Cosmetic Dentistry 3Health News:Healthpointe Is Now Offering EMG and NCV Diagnostics at All Clinics throughout Southern California. 2
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
(Date:5/29/2015)... May 29, 2015  Haemonetics Corporation (NYSE: HAE ... Operating Officer, will present at the JMP Securities Life ... on June 23 rd , 2015 at 11:30am Eastern ... Davies, presentation live via webcast at: http://wsw.com/webcast/jmp27/hae ... HAE ) is a global healthcare company dedicated to ...
(Date:5/29/2015)... May 29, 2015 Amgen (NASDAQ: ... pivotal Phase 3, global, randomized, placebo-controlled trials evaluating ... of secondary hyperparathyroidism (SHPT) in patients with chronic ... the primary endpoint, demonstrating that a greater proportion ... a greater than 30 percent reduction in parathyroid ...
Breaking Medicine Technology:LifeNet Health to add more than 160 jobs in 2015 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7
Cached News: